This page addresses first-line management of active chronic lymphocytic leukemia in a well-characterised patient profile — mutated IGHV status, confirmed absence of TP53 mutation and del(17p), and sufficient medical fitness for treatment.
Active CLL with mutated IGHV status, no TP53 mutation, and no del(17p) in a medically fit patient. This molecular and fitness profile defines the eligible population for this protocol and directly shapes the treatment strategy.
For medically fit patients presenting with this CLL profile, chemoimmunotherapy — with the specific regimen determined by the patient's age — is a primary treatment consideration, alongside certain targeted therapy options. The complete treatment algorithm, regimen selection criteria, and full list of alternatives are available in the structured protocol.